Empire State Development’s Post

The latest episode of our #OptimumPerspectivesPodcast is now live. #rarediseaseday2024

Listen 📣 to the expert view of our CEO Miquel Vila-Perello as he delves into the evolving field of #rarediseases and the cutting-edge research developments which have emerged over the last year in the #optimumperspectives special edition #podcast.   #biotech #ProteinSplicing #genetherapy #retinaldiseases #lifesciences #ShareYourColours

yes, we certainly do, it fits the bill I am presently with a great team to make this a reality in how it can be implemented in an ecologically sustainable manner whilst maintaining strong innovation Working antimicrobials secure society, health systems, food security and assure pandemic preparedness This is a vital agenda as we see a world increasingly immunosuppressed and where AMR continues to evolve at pace globally

Clarametyx Biosciences Secures $33M In Series A Funding To Propel Anti-Biofilm Technology Learn more & get our take 👇 https://lnkd.in/g-7Z6Y_b “We graciously welcome our new investors and appreciate the continued commitment of our existing investors. This successful raise enables us to expand our clinical evaluations of a platform that we believe will address critical unmet needs in infectious disease management,” – David V. Richards, Chief Executive Officer at Clarametyx Biosciences “Global health authorities continue to raise alarms about persistent bacterial infections and the rise in antimicrobial resistance associated with overuse of antibiotics. There is a clear and urgent need for novel technologies that can enhance the effectiveness of today’s antibiotics to address these challenging infections, and the Clarametyx technology represents a compelling strategy that we can propel into broader clinical studies to serve this need.” – Bill Baumel, Managing Director at Ohio Innovation Fund #funding #bioscience #SoHCNews

LYME AWARENESS MONTH DETROIT, Michigan, May 10th, 2024 -- Flightpath Biosciences Inc., a clinical-stage life sciences company developing therapeutics to treat infectious diseases, announced today that the first healthy volunteer participants have been dosed in its Phase I clinical trial of FP-100 (hygromycin A), an orally-available, narrow-spectrum antimicrobial drug candidate. The single center, prospective, randomized, double-blind, placebo-controlled study of single-ascending doses and multiple-ascending doses of FP-100 administered orally will include a maximum of 72 healthy adult volunteers to evaluate the safety, tolerability and pharmacokinetic profile of the drug. https://lnkd.in/gkPkFDep Invest Detroit Michigan Rise Ann Arbor SPARK Bay Area Lyme Foundation Global Lyme Alliance Project Lyme LymeDisease.org Illumina Ventures #LymeDisease #Lyme #tickbornedisease

Today, for #RareDiseaseDay, we're not just reflecting on the resilience and courage of patients facing uncommon challenges - this cause is profoundly personal to us at AdBio partners. Our commitment is not just corporate; it's embedded in the experiences of our managing partners, Alain Huriez and Geoffroy De Ribains. Both have been integral contributors to the rare disease landscape; Alain, first investor and driving force behind Orphalan, working on Wilson’s disease, and Geoffroy, ex-entrepreneur who created Step Pharma, focusing on innovative treatments for rare cancers. In collaboration with visionary entrepreneurs and cutting-edge researchers, we're proud to continue this legacy at AdBio partners. We create unique companies to address unmet medical needs, regardless of their prevalence, showcasing a patient-centric approach that transcends disease labels. Our mission is crystal clear: bridging the gap between scientific discovery and patient care. It's not just about groundbreaking discoveries; it's about translating those into cures. Today, as we highlight the challenges faced by rare disease patients, we're honored to be part of their journey, leveraging science to bring hope. Here is a glimpse of our portfolio companies dedicated to making a difference in the world of rare diseases. 🌟 #Adbio #PatientJourney #Innovation #Biotech EURORDIS-Rare Diseases Europe Rare Disease Day SparingVision Augustine Therapeutics Integra Therapeutics Calida Therapeutics ARTHEx Biotech Urania Therapeutics Tridek-One Tenpoint Therapeutics Ltd Anoat Therapeutics

The CF Foundation is investing up to $5 million in Clarametyx Biosciences to develop a drug that could help address difficult-to-treat bacteria such as chronic Pseudomonas aeruginosa, a major cause of lung infections in people with cystic fibrosis.  Our investment will support a Phase 1b/2a clinical trial of the drug (in combination with inhaled Tobramycin) in people with CF with Pseudomonas infections. If successful, future trials could expand to other bacterial infections. Learn more: https://lnkd.in/gHxAp9EH #cysticfibrosis

Sailing in tough weather ☁️ ? Poseidon CRO can help 🌊👇🏽 In the ocean of rare diseases and oncology research , many companies experience during their trials unfavourable winds and face a significant lack of recruitement which seriously impact the advancement of their pipeline development. Poseidon CRO stands at the forefront of innovation and brings the necessary solution for rescuing your trial. Our extensive network of sites and strategic partnerships with regulatory bodies enable us to not only streamline clinical trials but also to intervene and rescue stalled programs. By overcoming recruitment hurdles, we ensure that critical oncology and rare disease research continues to progress seamlessly. Connect with us on LinkedIn and reach out via mail : contact@poseidoncro.com to explore how we can elevate your research programs endeavors , help you navigate the regulatory and operational challenges and reach a safe port. #OncologyResearch #Innovation #GlobalReach #ClinicalTrials #raredisease

Congratulations to the team of Sfunga*, University of Illinois Urbana-Champaign and University of Wisconsin-Madison researchers on their Nature publication reporting on the #antifungal properties of the novel molecule AM-2-19. AM-2-19 is derivative of #amphotericin , rationally designed to mitigate toxicities and optimize antifungal activity. AM2-19, formulated as the development candidate, SF001, received FDA Fast Track and qualified infectious disease product (#QIDP) designations because of its potential to treat serious #infections lacking effective therapies. Sfunga is developing SF001, which is in Phase 1 clinical development.    *Sfunga is a #DeerfieldManagement portfolio company. https://lnkd.in/ev8hzeRh

Introducing Avrok's pre-blood collection screening service: Are you tired of costly screening experiences and delayed collection timelines due to patient inclusion/exclusion criteria? Avrok Biosciences offers a solution to streamline your process: 1. Efficient Self-Collection Kits: Avrok provides cost-effective self-collection sample kits shipped directly to patients. Each kit includes a return label for easy shipping back to Avrok's facility. 2. Expert Sample Analysis: Avrok swiftly handles the required sample analysis, determining patient eligibility for enrollment or disqualification. Common screenings include HLA type, infectious disease, or biomarker presence. 3. Convenient Phlebotomy Services: Upon successful screening, Avrok schedules a secondary, mobile phlebotomy-based collection to obtain the full volume blood sample from the patient, ensuring a seamless transition from screening to sample procurement. Partner with Avrok today to optimize the blood collection process and reduce costs associated with screening delays ➡ https://lnkd.in/dSeE2cmu #translationalresearch #cro #biobanking #patientcentricity